Fmr Llc ownership in IMVT / Immunovant, Inc.

Immunovant, Inc.

US ˙ NasdaqGS ˙ US45258J1025

Security	IMVT / Immunovant, Inc.
Institution	Fmr Llc
Latest Disclosed Ownership	14,729,554 shares
Ownership	8.40%

2025-11-05 - Fmr Llc has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 14,729,554 shares of Immunovant, Inc. (US:IMVT). This represents 8.4 percent ownership of the company. In their previous filing dated 2025-03-07 , Fmr Llc had reported owning 17,078,093 shares, indicating a decrease of -13.75 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2025-11-05	2025-11-05	13G/A	17,078,093	14,729,554	-13.75	8.40	-16.83
2025-03-07	2025-03-07	13G/A	12,537,571	17,078,093	36.22	10.10	17.92
2024-11-12	2024-11-12	13G/A	7,875,822	12,537,571	59.19	8.56	57.33
2024-02-09	2024-02-09	13G		7,875,822		5.44

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-15	2026-03-31	13F	IMMUNOVANT	COM	45258J102	16,947,888	-42,866	-0.25	420,986	-2.53	0.0044
2026-02-17	2025-12-31	13F	IMMUNOVANT	COM	45258J102	16,990,754	2,261,199	15.35	431,905	81.90	0.0220
2025-11-13	2025-09-30	13F	IMMUNOVANT	COM	45258J102	14,729,555	-3,869,640	-20.81	237,440	-20.21	0.0123
2025-08-14	2025-06-30	13F	IMMUNOVANT	COM	45258J102	18,599,195	1,358,160	7.88	297,587	1.00	0.0168
2025-05-12	2025-03-31	13F	IMMUNOVANT	COM	45258J102	17,241,035	4,143,120	31.63	294,649	-9.18	0.0188
2025-02-13	2024-12-31	13F	IMMUNOVANT	COM	45258J102	13,097,915	560,344	4.47	324,435	-9.24	0.0194
2024-11-13	2024-09-30	13F	IMMUNOVANT	COM	45258J102	12,537,571	2,053,688	19.59	357,446	29.15	0.0218
2024-08-13	2024-06-30	13F	IMMUNOVANT	COM	45258J102	10,483,883	2,827,938	36.94	276,775	11.89	0.0177
2024-05-13	2024-03-31	13F	IMMUNOVANT	COM	45258J102	7,655,945	-219,877	-2.79	247,364	-25.45	0.0166
2024-02-13	2023-12-31	13F	IMMUNOVANT	COM	45258J102	7,875,822	127,276	1.64	331,808	11.54	0.0255
2023-11-13	2023-09-30	13F	IMMUNOVANT	COM	45258J102	7,748,546	2,494,678	47.48	297,467	198.47	0.0257
2023-08-11	2023-06-30	13F	IMMUNOVANT	COM	45258J102	5,253,868	1,106,899	26.69	99,666	54.95	0.0084
2023-08-11	2023-03-31	13F/A-1	IMMUNOVANT	COM	45258J102	4,146,969	1,658,836	66.67	64,319	45.64	0.0059
2023-05-11	2023-03-31	13F	IMMUNOVANT	COM	45258J102	4,146,969	1,658,836		64,319		0.0012
2023-02-13	2022-12-31	13F	IMMUNOVANT	COM	45258J102	2,488,133	2,487,410	344,040.11	44,164	1,104,000.00	0.0044
2022-11-10	2022-09-30	13F	IMMUNOVANT	COM	45258J102	723	23	3.29	4	33.33	0.0000
2022-08-12	2022-06-30	13F	IMMUNOVANT	COM	45258J102	700	-193	-21.61	3	-40.00	0.0000
2022-05-13	2022-03-31	13F	IMMUNOVANT	COM	45258J102	893	893		5		0.0000
2021-02-08	2020-12-31	13F	IMMUNOVANT	COM	45258J102	0	-200,000	-100.00	0	-100.00
2020-11-13	2020-09-30	13F	IMMUNOVANT	COM	45258J102	200,000	200,000		7,038		0.0007

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.